SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.58+1.4%Nov 5 12:44 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg10/17/2007 2:02:21 AM
   of 2240
 
J and J Q3 CC:

We remain on track to file three additional medicines for approval by the end of this year: Dapoxetine for premature ejaculation in the EU, CNTO 1275 for psoriasis and paliperidone palmitate for schizophrenia. We announced positive data on CNTO 1275 at the World Congress of Dermatology in Buenos Aires earlier this month. More than two-thirds of patients with moderate to severe plaque psoriasis, receiving two doses of CNTO 1275, achieved at least 75% reduction in psoriasis at week 12, the primary endpoint of the study.
.
.
.
Unidentified Analyst

First a pharma pipeline question and then maybe a couple of questions for Nick since we have him here. The pharma pipeline question is on CNTO 148. We are going to see data in a couple of weeks at ACR, I believe in arthritis and ankylosing spondylitis. Could you talk about your filing strategy for different indications for 148 RA as well as arthritis and so forth?

Nick Valeriani

On the pharma pipeline question on CNTO 148 – Louise, help me out here if I have missed one – our strategy there is in early '08 we intend to file three indications: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. So all three indications are planned to be filed in early '08.

seekingalpha.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News